HIV Infection Risk Behaviors and Methadone Treatment: Client-Reported HIV Infection in a Follow-up Study of Injecting Drug Users in New England

References

• Nicolosi A., Musicco M., Sarocco A., et al. Incidence and risk factors of HIV infection: A prospective study of seronegative drug users from Milan and Northern Italy, 1987-1989. Epidemiology 1990; 1: 453–459
   PubMedGoogle Scholar
• Schoenbaum E. E., Hartel D., Selwyn P. A., et al. Risk factors for Human Immunodeficiency Virus infection in intravenous drug users. N. Engl. J. Med. 1989; 321: 874–879
   PubMed Web of Science ®Google Scholar
• Des Jarlais D. C., Choopanya K., Vanichseni S., et al. AIDS risk reduction and reduced HIV seroconversion among injection drug users in Bangkok. Am. J. Public Health 1994; 84: 452–455
   PubMed Web of Science ®Google Scholar
• Metzger D. S., Woody G. E., McLellan T., et al. Human Immunodeficiency Virus seroconversion among intravenous drug uses in- and out-of-treatment: An 18-month prospective follow-up. J. Acquir. Immun. Defic. Syndr. 1993; 6: 1049–1056
   PubMed Web of Science ®Google Scholar
• Zangerle R., Fuchs D., Rossler H., et al. Trends in HIV infection among intravenous drug users in Innsbruck, Austria. J. Acquir. Immun. Defic. Syndr. 1992; 5: 865–871
   PubMedGoogle Scholar
• Friedman S. R., Benny J., Deren S., et al. Risk factors for Human Immunodeficiency Virus Seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am. J. Epidemiol. 1995; 142: 864–874
   PubMed Web of Science ®Google Scholar
• van Ameijden E. J. C., van den Hoek J. A. R., van Haastrecht H. J. A., et al. The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. Am. J. Epidemiol. 1992; 136: 236–243
   PubMed Web of Science ®Google Scholar
• Nicolosi A., Leite M. L., Cmusicco M., et al. Parenteral and sexual transmission of Human Immunodeficiency Virus in intravenous drug users: A study of seroconversion. Am. J. Epidemiol. 1992; 135: 225–233
   PubMed Web of Science ®Google Scholar
• Moss A. R., Vranizan K., Gorter R., et al. HIV seroconversion in intravenous users in San Francisco, 1985-1990. AIDS 1994; 8: 223–231
   PubMed Web of Science ®Google Scholar
• Astemborski J., Vlahov D., Warren D., et al. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am. J. Public Health 1994; 84: 382–387
   PubMed Web of Science ®Google Scholar
• AIDS in Connecticut, Annual Surveillance Report. December 31, 1992
   Google Scholar
• Massachusetts Department of Health. AIDS Surveillance Program 1992
   Google Scholar
• Holmberg S. D. The estimated prevalence and incidence of HIV in 96 large metropolitan areas. Am. J. Public Health 1996; 86: 642–654
   PubMed Web of Science ®Google Scholar
• Swanson N., Patton C, McNamara R., et al. HIV counseling and testing evaluation study: Ethnographic component final report. January, 1994, Unpublished Data
   Google Scholar
• Centers for Disease Control, Risk behaviors for HIV transmission among intravenous-drug users not in treatment-United States, 1987-1989. MMWR Morb Mortal Wkly Rep. 1990; 39: 273–276
   PubMedGoogle Scholar
• Selvin S. Statistical Analysis of Epidemiologic Data. Oxford University Press. 1991
   Google Scholar
• PHREG procedure, SAS Technical Report P-229 SAS/STAT Software: Changes and Enhancements, Release 6.07. SAS Institute, CaryNorth Carolina 1991
   Google Scholar
• Solomon L., Astemborski J., Warren D., et al. Differences in risk factors for human immunodeficiency virus Type 1 seroconversion among male and female intravenous drug users. Am. J. Epidemiol. 1993; 137: 892–8
   PubMed Web of Science ®Google Scholar
• Hahn R. A., Onorato I. M., Jones S. T., et al. Prevalence of HIV infection among intravenous drug users. JAMA 1989; 261: 2677–2684
   PubMed Web of Science ®Google Scholar
• Robles R. R., Colon H. M., Sahai H., et al. Behavioral risk factors and Human Immunodeficiency Virus prevalence among intravenous drug users in Puerto Rico. Am. J. Epidemiol. 1992; 135: 531–540
   PubMed Web of Science ®Google Scholar
• Chaisson R. E., Bacchetti P., Osmond D. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261: 561–565
   PubMed Web of Science ®Google Scholar
• Massachusetts Department of Public Health-AIDS Bureau, HIV Seropositivity Follow-up/ CISS Program, 1993 CICS Aggregate Report. March 21, 1994
   Google Scholar
• Vlahov D. HIV seroconversion studies among intravenous drug users. AIDS 1994; 8: 263–265
   PubMedGoogle Scholar
• Battjes R. J., Pickens R. W., Amsel Z., et al. Heterosexual transmission of Human Immunodeficiency Virus among intravenous drug users. J. of Inf. Diseases 1990; 162: 1007–1011
   PubMed Web of Science ®Google Scholar
• Chaisson R. E., Moss A. R., Onishi R., et al. Human Immunodeficiency Virus infection in heterosexual intravenous drug users in San Francisco. Am. J. Public Health 1987; 77: 169–172
   PubMed Web of Science ®Google Scholar
• McCusker J., Stoddard A. M., McCarthy E. The validity of self-reported HIV antibody test results. Am. J. Public Health 1992; 82: 567–569
   PubMed Web of Science ®Google Scholar
• Schutz C. G., Vlahov D., Anthony J. C, et al. Comparison of self-reported injection frequencies for past 30 days and 6 months among intravenous drug users. J. Clin. Epidemiol. 1994; 47: 191–195
   PubMed Web of Science ®Google Scholar
• Anthony J. C, Vlahov D., Celentano D. D., et al. Self-report interview data for a study of HIV-1 infection among intravenous drug users: Description of methods and preliminary evidence on validity. J. Drug Issues 1991; 21: 739–757
   Web of Science ®Google Scholar
• Ehrman R. M., Robbins S. J. Reliability and validity of 6-month timeline reports of cocaine and heroin use in a methadone population. J. Consult. Clin. Psychology 1994; 62: 843–850
   PubMed Web of Science ®Google Scholar